REFERENCES
- Gulick RM, Ribaudo HJ, Shikuma CM, et al., for the AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the ini-tial treatment of HIV-1 infection. N Engl J Med. 2004; 350:1850–1861.
- van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients (AT-LANTIC). AIDS. 2003;17:987–999.
- Staszewski S, Keiser P, Montaner J, et al., for the CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001285: 1155–1163.
- Gerstoft J, Kirk O, Obel N, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS. 2003;17:2045–2052.
- Jemsek J, Hutcherson P, Harper E. Poor virologic re-sponses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir OF. In: Program and abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections; February 2004; San Francisco, CA. Abstract 51. Available at: http://www.retroconference.org/2004/cd/Abstract/51.htm. Accessed January 10, 2005.
- Arribas JR. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. J Antimicrob Chemother. 2004;54:587–592.
- Gallant JE, Rodriguez AE, Weinberg WG, et al., for the ESS30009 Study. Early virologic non response to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192(11):1921–1930.
- Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin. 2004;20:1103–1114.
- Matheron S, Descamps D, Boué F, et al., on behalf of the CNAF3007 study group. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/ lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther. 2003;8:163–171.
- Kumar P, Rodriguez-French A, Thompson M, Tashima K, Wannamaker P, Williams V, Pappa K. Prospective study of hyperlipidemia in ART-naïve subjects taking Trizivir (TZV), Combivir (COM)/Nelfinavir (NFV), or stavudine (d4T)/ lamivudine (3TC)/NFV. Antivir Ther. 2003;8\(suppl 1):5380.
- Bartlett JA, Johnson J, Herrera G, Sosa N, Rodriguez AE, Shaefer MS. Abacavir/lamivudine (ABC/3TC) in combina-tion with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): E5540001 (CLASS) preliminary 48-week results. In: Program and abstracts of the XIV International AIDS Conference; 2002; Barcelona, Spain. Geneva, Swit-zerland: The International AIDS Society. Abstract TuOrB1189.
- van Leth F, Phanuphak P, Ruxrungtham K, et al., 2NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253–1263.
- Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, O'Shaughnessy MV, Montaner JSG. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer viro-logic response than suppression below the limit of quantitation. J Infect Dis. 1999;180:1347–1350.
- Greub G, Cozzi-Lepri A, Ledergerber B, et al., for the Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral re-bound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967–1969.
- Shaefer MS. Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen. Ann Pharmacother. 2004;38:1314–1316.